1. Leise M, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clinic Proceedings.2014;89(1):95-106.
2. Chalasani N, Bonkovsky HL, Fontana R, Lee W. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology.2015;148(7):1340-1352.e1347.
3. Stultz JS, Eiland LS. Doxycycline and Tooth Discoloration in Children: Changing of Recommendations Based on Evidence of Safety. Ann pharmacother.2019;53(11):1162-1166.
4. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs.2004;64(1):63.
5. Karakonstantis S, Kritsotakis EI, Gikas A. Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems. Infection.2020;48(6):835-851.
6. Mei H, Yang T, Wang J, Wang R, Cai Y. Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis. The Journal of antimicrobial chemotherapy.2019;74(12):3423-3431.
7. Lebrun-Vignes B, Kreft-Jais C, Castot A, Chosidow O. Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. The British journal of dermatology.2012;166(6):1333-1341.
8. Smith K, Leyden JJ. Safety of doxycycline and minocycline: A systematic review. Clin Ther.2005;27(9):1329-1342.
9. Bettesda(MD). Liver Tox: Clinical and research information on drug-induced liver injury. . PubMed.2019;https://www.ncbi.nlm.nih.gov/books/NBK548040/ Last update: April 10, 2019.
10. Allen ES, Brown WE. Hepatic toxicity of tetracycline in pregnancy. American journal of obstetrics and gynecology.1966;95(1):12-18.
11. Peters RL, Edmondson HA, Mikkelsen WP, Tatter D. Tetracycline-induced fatty liver in nonpregnant patients. A report of six cases. American journal of surgery.1967;113(5):622-632.
12. Chen Z, Shi X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Medicine.2018;97(38):e12467.
13. Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scandinavian journal of gastroenterology.2005;40(9):1095-1101.
14. Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. Journal of clinical pharmacy and therapeutics.2007;32(5):483-487.
15. Chatterjee S, Annaert P. Drug-induced cholestasis: mechanisms, models, and markers. Current drug metabolism.2018;19(10):808-818.
16. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and drug safety.2001;10(6):483-486.
17. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. European journal of clinical pharmacology.1998;54(4):315-321.
18. Duggirala HJ, Tonning JM, Smith E, et al. Use of data mining at the Food and Drug Administration. Journal of the American Medical Informatics Association : JAMIA.2016;23(2):428-434.
19. FDA. FDA adverse event reporting system (FAERS) quarterly data extract files. 2021;https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html Accessed 29 January 2021.
20. Bin WU, Feng-Bo WU, Luo M, Qin Z, Ting XU. Application of MedEx in FAERS drug names standardization. China J of Hosp Pharm.2019;39:1989-1992.
21. Xu H, Stenner SP, Doan S, Johnson KB, Waitman LR, Denny JC. MedEx: a medication information extraction system for clinical narratives. Journal of the American Medical Informatics Association : JAMIA.2010;17(1):19-24.
22. Suzuki A, Yuen NA, Ilic K, et al. Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™. Regulatory toxicology and pharmacology : RTP.2015;72(3):481-490.
23. Hunt CM, Yuen NA, Stirnadel-Farrant HA, Suzuki A. Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database. Regulatory toxicology and pharmacology : RTP.2014;70(2):519-526.
24. Dowling HF, Lepper MH. Hepatic reactions to tetracycline. Jama.1964;188:307-309.
25. Schultz JC, Adamson JS, Jr., Workman WW, Norman TD. Fatal liver disease after intravenous administration of tetracycline in high dosage The New England journal of medicine.1963;269:999-1004.
26. Lawrenson RA, Seaman HE, Sundström A, Williams TJ, Farmer RD. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug safety.2000;23(4):333-349.
27. Nietsch HH, Libman BS, Pansze TW, Eicher JN, Reeves JR, Krawitt EL. Minocycline-induced hepatitis. The American journal of gastroenterology.2000;95(10):2993-2995.
28. Rubinstein E, Vaughan D. Tigecycline: a novel glycylcycline. Drugs.2005;65(10):1317-1336.
29. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.2005;9(5):251-261.
30. Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. The Lancet Infectious diseases.2011;11(11):834-844.
31. Kadoyama K, Sakaeda T, Tamon A, Okuno Y. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system. Biological & pharmaceutical bulletin.2012;35(6):967-970.
32. Borsuk-De Moor A, Rypulak E, Potręć B, et al. Population pharmacokinetics of high-dose tigecycline in patients with sepsis or septic shock. Antimicrobial agents and chemotherapy.2018;62(4):e02273-02217.
33. Zha L, Pan L, Guo J, French N, Villanueva EV, Tefsen B. Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis. Advances in therapy.2020;37(3):1049-1064.